A5055025989- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Prostate Cancer Diagnosis and Treatment
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Ureteral procedures and complications
- Radiopharmaceutical Chemistry and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Pediatric Urology and Nephrology Studies
- Cancer, Lipids, and Metabolism
- Renal Transplantation Outcomes and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Kidney Stones and Urolithiasis Treatments
- Reproductive Biology and Fertility
- Hormonal and reproductive studies
- Cancer Diagnosis and Treatment
- Building materials and conservation
- Homicide, Infanticide, and Child Abuse
- Organ Transplantation Techniques and Outcomes
- Cancer Mechanisms and Therapy
- Multiple Myeloma Research and Treatments
Hospital Universitari Germans Trias i Pujol
2010-2025
Bellvitge University Hospital
2005-2025
Institut Català d'Oncologia
2021-2025
Universitat de Barcelona
2024
Universitat Autònoma de Barcelona
2016-2017
4505 Background: Bladder-preserving combined-modality therapies constitute an alternative to radical cystectomy for selected pts with MIBC. In preclinical studies, combination of radiation and dual checkpoint blockade appears activate non-redundant immune mechanisms, potentiating antitumor activity. The purpose the present study is explore feasibility, toxicity activity this approach in Methods: Pts localized MIBC clinical stages T2-4a N0 M0, ECOG 0-1, without contraindications...
801 Background: Despite standard-of-care therapy with transurethral resection of bladder tumor and intravesical BCG instillation, a significant percentage patients non-muscle invasive cancer (NMIBC) experience disease recurrence or progression. Therefore, novel combination therapies are needed to improve efficacy. The RUTIVAC-1 trial, randomized, double-blind, placebo-controlled, phase I study, was conducted investigate the potential heterologous prime-boost strategy using RUTI, nonlive...
TPS884 Background: Neoadjuvant cisplatin-based chemotherapy (NACT) has demonstrated a 5-8% improvement in 5-year overall survival (OS) patients (pts) with muscle invasive bladder cancer (MIBC). However, its routine implementation is still low due to concerns about toxicity/efficacy. Also, 50% of pts are considered cisplatin ineligible and therefore unable receive NACT. Immune-checkpoint inhibitors (ICI) antibody drug conjugates (ADC) have separately clinical activity the perioperative...
850 Background: Neoadjuvant therapy before radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). However, a significant number of patients do not respond to these therapies. Identifying biomarkers predictive response and developing novel therapeutic strategies are crucial improving patient management survival. This study aims investigate non-invasive that can predict neoadjuvant in MIBC explore their potential use design new Methods: Immunophenotyping...
Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown benefit a subset of patients, but mechanistic basis and biomarkers remain elusive. To identify mechanisms response indicators for antitumor efficacy taxane-platinum mCRPC. Transcriptomic data from publicly available mCRPC dataset taxane-exposed...
Abstract Objective To evaluate the efficacy and safety of apalutamide prostate cancer compared to pivotal trials patients identify first subsequent therapy in a real‐world setting. Methods The study is prospective observational based on evidence, performed by different medical disciplines eight academics centres around Barcelona, Spain. It included all with metastatic hormone‐sensitive (mHSPC) high‐risk non‐metastatic castration‐resistant (nmCRPC) treated from June 2018 December 2022....
Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage will still progress, highlighting need to identify more likely benefit from AA. Parameters linked prostate-specific antigen (PSA) kinetics are promising prognostic markers. We have examined clinical and PSA-related factors potentially associated overall survival (OS) treated AA.Between 2011 2014, 104 mCRPC AA after progression...
TPS4588 Background: Cisplatin-based neoadjuvant chemotherapy (CT) followed by cystectomy improves overall survival in patients (pts) with MIBC. Immune checkpoint inhibitors as single agents are approved pts advanced UC. Combination of both programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) checkpoints might be synergistic. Durvalumab (DU) is a selective, engineered, human IgG1 monoclonal antibody (mAb) that blocks PD-L1 binding to PD-1 CD80....
388 Background: Multidisciplinary Tumor Boards are an essential component of patient management, as they integrate input from various healthcare professionals to make comprehensive decisions about care. Management patients with genitourinary (GU) tumors particularly relies on these multidisciplinary Boards. However, there no guidelines how groups should operate. Methods: A systematic literature review was conducted identify criteria useful evaluate quality in GU (GUTB); publication dates...
ABSTRACT Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit NAC remains unclear for many patients due lack reliable biomarkers predicting treatment response. In order identify and build an integrated highly accurate model predict response, we performed a comprehensive transcriptomic genomic profiling on tumors from 100 MIBC patients. Our results showed that expression top genes...
4595 Background: Multiple molecular predictors have been associated with response to ICI in metastatic UC (mUC), including clonal TMB, APOBEC mutagenesis and multiple RNA signatures. Tumor-intrinsic tumor-extrinsic (microenvironmental) properties can drive resistance PD-1/PD-L1 inhibitors, although the factors that determine specifically MIBC remains incompletely characterized. Epigenomic analysis combined single cell (sc) technology reveal mechanisms of involving both cancer cells...
Background. Approximately 5% to 10% of patients who undergo kidney transplantation develop ureteral stricture, which can be treated endoscopically or by open surgery, is more effective but complications are common and potentially severe. Robotic surgery has begun emerge as an alternative in reconstructive procedures. However, few studies have evaluated the role robotic this clinical setting. The aim study was assess efficacy safety treating stricture after transplantation. Methods....